Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -84.56% | +114.83% | -55.26% | -26.12% | -61.32% |
| Gross Profit Growth | -84.56% | +114.83% | -63.38% | -2006.71% | +968.95% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +36.68% | +13.25% | +10.12% | +14.68% | +5.50% |
| Weighted Average Shares Diluted Growth | +36.68% | +13.25% | +10.12% | +14.68% | +5.50% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -867.98% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -94.95% | +885.22% | +2247.42% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +69.87% | +5.77% | +36.93% | +6.49% | +78.20% |
| Book Value per Share Growth | +54.79% | -2.38% | +28.81% | -7.59% | +79.18% |
| Debt Growth | +3.65% | -0.79% | -2.80% | -4.80% | -6.28% |
| R&D Expense Growth | +35.58% | +64.39% | +32.41% | +22.65% | +16.77% |
| SG&A Expenses Growth | +14.80% | +13.20% | +1.57% | +12.17% | +3.77% |